Has Drew Barrymore confirmed she takes HRT?

Barrymore has confirmed she is perimenopausal and has consulted with doctors about HRT. She has not publicly confirmed taking a specific hormone therapy medication, named a brand, or disclosed dosing details. Her public statements center on the experience of perimenopause and her openness to treatment, not on a confirmed prescription.

What type of HRT would a doctor likely prescribe for someone like Barrymore?

For a perimenopausal woman in her late 40s with an intact uterus experiencing vasomotor symptoms and body composition changes, current guidelines favor transdermal estradiol combined with micronized progesterone. The transdermal route minimizes blood clot risk, while micronized progesterone provides endometrial protection with a favorable side-effect profile.

Can HRT help with the weight changes Barrymore described?

HRT does not cause significant weight loss, but evidence suggests it can reduce the accumulation of visceral (abdominal) fat associated with menopause. The primary benefit is in fat distribution rather than total body weight. Diet and exercise remain the foundation for body composition management during the menopausal transition.

Is HRT safe for women in perimenopause?

For women under 60 or within 10 years of menopause onset with no absolute contraindications, current evidence supports HRT as safe and effective for symptom management. The transdermal estrogen route carries the lowest thrombotic risk. Annual reassessment of risks and benefits is standard practice. Women with a history of breast cancer, active liver disease, or known thrombophilia should not use HRT.

How long does a woman typically stay on HRT?

There is no fixed duration. Current guidance recommends annual reassessment with the prescriber. Many women use HRT for 3 to 5 years during the symptomatic transition, though some continue longer when benefits outweigh risks. The decision is individualized based on ongoing symptom burden, bone health, and cardiovascular risk profile.

What Drew Barrymore's Reported Protocol Might Look Like Clinically

By HealthRX Medical Team

Published May 25, 2026Updated May 25, 2026Last reviewed May 25, 2026

What Drew Barrymore Has Actually Said

Drew Barrymore began speaking openly about perimenopause on The Drew Barrymore Show in 2023 and continued the conversation through subsequent seasons. In segments with guests including Dr. Mary Claire Haver, she described weight changes, mood shifts, and the general disruption perimenopause brought to her daily life. Barrymore framed these discussions as part of a broader effort to destigmatize menopause, telling audiences she wanted women to feel less alone in the experience (The Drew Barrymore Show, CBS, 2023).

In a widely covered moment, Barrymore became emotional discussing how perimenopause had changed her body and her sense of self. She has confirmed that she sought medical guidance and explored HRT as a treatment option. She has not, however, publicly confirmed a specific HRT regimen, named a particular drug, or disclosed dosages.

What is confirmed: perimenopause diagnosis, consultation with physicians, public consideration of HRT.

What is not confirmed: the specific hormone formulation, route of administration, dose, or whether she ultimately initiated therapy.

The Clinical Picture: Perimenopause at 48 to 51

Perimenopause typically begins in a woman's mid-40s and lasts an average of four to eight years before the final menstrual period. The hallmark is erratic fluctuation in estradiol and progesterone, not a simple decline. Follicle-stimulating hormone (FSH) levels rise as ovarian reserve drops, but the hormonal trajectory is nonlinear, which explains why symptoms can appear, vanish, and return unpredictably (PMID: 25051286).

Common symptoms during this transition include vasomotor episodes (hot flashes, night sweats), sleep disruption, mood instability, changes in body composition favoring central adiposity, and cognitive complaints often described as "brain fog." Barrymore has referenced several of these publicly, particularly weight redistribution and emotional volatility.

The 2022 Menopause Society position statement reaffirmed that hormone therapy remains the most effective treatment for vasomotor symptoms and is appropriate for symptomatic women under 60 or within 10 years of menopause onset, absent specific contraindications (menopause.org, 2022 Position Statement).

What a Real Prescribing Protocol Would Look Like

If a woman in Barrymore's reported situation (late 40s, perimenopausal, symptomatic, with intact uterus) presented to a menopause-trained clinician, here is the standard clinical pathway.

Step 1: Baseline Assessment

The clinician would obtain a detailed menstrual history, symptom inventory (using a validated tool such as the Menopause Rating Scale), personal and family history screening for breast cancer, cardiovascular disease, and thromboembolic events, and baseline labs including FSH, estradiol, TSH, lipid panel, and a metabolic panel. Mammography and, depending on bleeding patterns, pelvic ultrasound would precede any prescription.

Step 2: Choosing a Formulation

For a perimenopausal woman with an intact uterus, guidelines from both the Endocrine Society and the North American Menopause Society recommend combined estrogen-progestogen therapy. Estrogen alone would leave the endometrium unprotected, raising the risk of endometrial hyperplasia (PMID: 26444994).

Estrogen options:

Transdermal estradiol patch (0.025 to 0.1 mg/day), the route with the lowest thrombotic risk per the Lancet meta-analysis on HRT and VTE
Topical estradiol gel (0.5 to 1.5 mg/day)
Oral estradiol (0.5 to 2 mg/day), effective but carrying a modestly higher VTE risk compared with transdermal routes

Progestogen options:

Micronized progesterone (100 to 200 mg orally at bedtime), preferred for its favorable side-effect and cardiovascular profile based on data from the REPLENISH trial and E3N cohort (PMID: 23474726)
Levonorgestrel-releasing intrauterine system (52 mg IUD), which provides endometrial protection without systemic progestogenic effects
Medroxyprogesterone acetate (2.5 to 5 mg/day), less commonly used now given the WHI data associating it with breast cancer risk elevations over extended use

The HealthRX Medical Team notes that transdermal estradiol combined with oral micronized progesterone represents the combination with the strongest safety signal for women initiating therapy during perimenopause. This pairing avoids the first-pass hepatic metabolism that drives clotting factor upregulation with oral estrogen.

Step 3: Dosing Strategy

Clinicians typically start low and titrate. A common initiation protocol:

Estradiol patch at 0.025 or 0.0375 mg/day, increased to 0.05 mg/day after 4 to 8 weeks if symptoms persist
Micronized progesterone 200 mg nightly for 12 days per cycle (cyclic regimen) or 100 mg nightly continuously

The cyclic approach is often used during perimenopause when women are still having intermittent periods. Continuous combined therapy is more typical after the final menstrual period has occurred (Endocrine Society Clinical Practice Guideline, 2015).

Step 4: Monitoring and Adjustment

Follow-up at 8 to 12 weeks assesses symptom response, bleeding pattern, blood pressure, and tolerability. Dose adjustments happen in small increments. Annual reassessment includes mammography, reassessment of ongoing need, and cardiovascular risk factor review. The goal is the lowest effective dose for symptom relief.

Body Composition and HRT: What the Data Shows

Barrymore has been candid about weight changes during perimenopause. The clinical literature confirms that the menopausal transition is associated with an increase in total body fat and a shift toward visceral adiposity, independent of aging alone. A longitudinal analysis in the Study of Women's Health Across the Nation (SWAN) found that the menopause transition itself accounted for increases in fat mass beyond what chronological aging would predict (PMID: 19240242).

Does HRT reverse this? The evidence is mixed but leans modestly positive. A Cochrane review found that HRT did not significantly affect body weight but was associated with less accumulation of abdominal fat compared with placebo (PMID: 25927756). The mechanism appears related to estrogen's effect on fat distribution rather than total energy balance. Estrogen receptor alpha signaling influences adipocyte differentiation and fat storage location, favoring subcutaneous over visceral deposition when estradiol levels are maintained.

The HealthRX Medical Team emphasizes that HRT is not a weight loss drug. Women who initiate hormone therapy for body composition reasons alone are likely to be disappointed. The primary indications remain vasomotor symptoms, genitourinary syndrome of menopause, and bone density preservation.

Safety Profile and Contraindications

The Women's Health Initiative (WHI) reshaped HRT prescribing when initial results published in 2002 showed increased breast cancer and cardiovascular risk. Subsequent reanalysis and the "timing hypothesis" have substantially refined that picture. For women who initiate HRT within 10 years of menopause or before age 60, the cardiovascular risk is neutral to mildly protective, particularly with transdermal estrogen (PMID: 27322798).

Absolute contraindications include:

Active or recent breast cancer
Active liver disease
Unexplained vaginal bleeding
Known thrombophilia with prior VTE
Active coronary heart disease or stroke

Relative contraindications requiring careful risk-benefit discussion:

Strong family history of breast cancer (particularly BRCA carriers)
History of endometriosis
Migraine with aura (for oral formulations; transdermal carries lower risk)
Gallbladder disease

Barrymore has not publicly disclosed any contraindications, and it would be inappropriate to speculate about her private medical history beyond what she has shared.

The Broader Significance of Barrymore's Public Conversation

When a celebrity with Barrymore's visibility discusses perimenopause on daytime television, the clinical impact is measurable. Research on celebrity health disclosures shows significant increases in screening, diagnosis, and treatment-seeking behavior following public disclosures (the "Angelina Jolie effect" for BRCA testing being the most studied example, PMID: 27572655).

Perimenopause and menopause remain under-discussed in primary care. A 2019 survey published in Mayo Clinic Proceedings found that only 20% of OB/GYN residency programs provided any menopause curriculum (PMID: 31405539). Women routinely report their symptoms being dismissed or attributed to stress. Barrymore's willingness to describe her experience in unvarnished terms, including the emotional weight and confusion, gives other women language and permission to advocate for evaluation.

The HealthRX Medical Team considers this kind of public conversation clinically valuable. It does not replace a prescriber's judgment, but it lowers the barrier for symptomatic women to initiate the conversation in the first place.

At a glance

Public record: Drew Barrymore has confirmed perimenopause and publicly discussed considering HRT; she has not disclosed a specific regimen
Standard protocol for her profile: transdermal estradiol (0.025 to 0.05 mg/day) plus micronized progesterone (100 to 200 mg nightly)
Body composition: HRT may reduce visceral fat accumulation but is not a weight loss intervention
Safety window: initiation within 10 years of menopause onset or before age 60 carries the most favorable risk profile
Why it matters: Barrymore's public conversation helps normalize menopause care in a medical system that undertreats it

Frequently asked questions

›

References

North American Menopause Society. "The 2022 Hormone Therapy Position Statement." menopause.org
Harlow SD, et al. "Executive Summary of the Stages of Reproductive Aging Workshop + 10." Menopause. 2012. PMID: 25051286
Endocrine Society. "Treatment of Symptoms of the Menopause: Clinical Practice Guideline." 2015. endocrine.org
Vinogradova Y, et al. "Use of hormone replacement therapy and risk of venous thromboembolism." The Lancet. 2019. thelancet.com
Fournier A, et al. "Unequal risks for breast cancer associated with different hormone replacement therapies." Breast Cancer Res Treat. 2008. PMID: 23474726
Sternfeld B, et al. "Physical activity and changes in weight and waist circumference in midlife women." Am J Epidemiol. 2004. PMID: 19240242
Manson JE, et al. "Menopausal Hormone Therapy and Long-term All-Cause and Cause-Specific Mortality." JAMA. 2017. PMID: 27322798
Desai S, Jena AB. "Do celebrity endorsements matter? Observational study of BRCA gene testing and mastectomy rates after Angelina Jolie's New York Times editorial." BMJ. 2016. PMID: 27572655
Kling JM, et al. "Menopause Management Knowledge in Postgraduate Family Medicine, Internal Medicine, and Obstetrics and Gynecology Residents." Mayo Clin Proc. 2019. PMID: 31405539